Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822–1832 (2019). This manuscript offers a comprehensive review of the role of chronic low-grade inflammation in systemic disease, including obesity-related pathophysiologies.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradley, D., Deng, T., Shantaram, D. & Hsueh, W. A. Orchestration of the adipose tissue immune landscape by adipocytes. Annu. Rev. Physiol. 86, 199–223 (2024).

Article  CAS  PubMed  Google Scholar 

Hagberg, C. E. & Spalding, K. L. White adipocyte dysfunction and obesity-associated pathologies in humans. Nat. Rev. Mol. Cell Biol. 25, 270–289 (2024).

Article  CAS  PubMed  Google Scholar 

Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 13, 633–643 (2017).

Article  CAS  PubMed  Google Scholar 

Shaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. Nat. Rev. Endocrinol. 20, 136–148 (2024).

Article  CAS  PubMed  Google Scholar 

Xourafa, G., Korbmacher, M. & Roden, M. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 20, 27–49 (2024).

Article  PubMed  Google Scholar 

Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J. Am. Coll. Cardiol. 71, 2392–2401 (2018). This study shows that although inhibiting IL-1β in patients who have had a myocardial infarction and CRP levels ≥2 mg/l prevents further cardiovascular events, it has no effect on reducing their risk of developing diabetes mellitus.

Article  CAS  PubMed  Google Scholar 

Li, D., Zhong, J., Zhang, Q. & Zhang, J. Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus. Front. Immunol. 14, 1125116 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017). This study provides definitive evidence that inhibiting IL-1β in patients who have had a myocardial infarction and CRP levels ≥2 mg/l prevents further cardiovascular events.

Article  CAS  PubMed  Google Scholar 

Antonelli, M. & Kushner, I. It’s time to redefine inflammation. FASEB J. 31, 1787–1791 (2017).

Article  CAS  PubMed  Google Scholar 

Medzhitov, R. The spectrum of inflammatory responses. Science 374, 1070–1075 (2021).

Article  CAS  PubMed  Google Scholar 

Meizlish, M. L., Franklin, R. A., Zhou, X. & Medzhitov, R. Tissue homeostasis and inflammation. Annu. Rev. Immunol. 39, 557–581 (2021).

Article  CAS  PubMed  Google Scholar 

Sugimoto, M. A., Sousa, L. P., Pinho, V., Perretti, M. & Teixeira, M. M. Resolution of inflammation: what controls its onset? Front. Immunol. 7, 160 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Serhan, C. N. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol. Asp. Med. 58, 1–11 (2017).

Article  Google Scholar 

Wallace, J. L., Ianaro, A., Flannigan, K. L. & Cirino, G. Gaseous mediators in resolution of inflammation. Semin. Immunol. 27, 227–233 (2015).

Article  CAS  PubMed  Google Scholar 

Perretti, M. & D’Acquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62–70 (2009).

Article  CAS  PubMed  Google Scholar 

Schett, G. & Neurath, M. F. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat. Commun. 9, 3261 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Brennan, E., Kantharidis, P., Cooper, M. E. & Godson, C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 17, 725–739 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiang, N. & Serhan, C. N. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol. Asp. Med. 58, 114–129 (2017). This review provides an elegant and comprehensive overview of the synthesis, receptors and function of SPMs.

Article  CAS  Google Scholar 

Fredman, G. & Serhan, C. N. Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-023-00984-x (2024).

Panigrahy, D., Gilligan, M. M., Serhan, C. N. & Kashfi, K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol. Ther. 227, 107879 (2021).

Article  CAS  PubMed  Google Scholar 

Pirault, J. & Back, M. Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front. Pharmacol. 9, 1273 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalli, J. & Serhan, C. N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60–e72 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doran, A. C., Yurdagul, A. Jr. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).

Article  CAS  PubMed  Google Scholar 

Julliard, W. A. et al. Specialized pro-resolving mediators as modulators of immune responses. Semin. Immunol. 59, 101605 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borgeson, E. et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metab. 22, 125–137 (2015). This study shows that lipoxin treatment of mice alleviates obesity-related adipose tissue inflammation, as well as kidney and liver disease.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borgeson, E. et al. Lipoxin A4 attenuates adipose inflammation. FASEB J. 26, 4287–4294 (2012).

Article  CAS  PubMed  Google Scholar 

Cheng, T. et al. Resolvin D1 improves the Treg/Th17 imbalance in systemic lupus erythematosus through miR-30e-5p. Front. Immunol. 12, 668760 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez-Hernandez, J., Chiurchiu, V., Perruche, S. & You, S. Regulation of T-cell immune responses by pro-resolving lipid mediators. Front. Immunol. 12, 768133 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramon, S., Bancos, S., Serhan, C. N. & Phipps, R. P. Lipoxin A4 modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur. J. Immunol. 44, 357–369 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, N. et al. Lipoxin B4 enhances human memory B cell antibody production via upregulating cyclooxygenase-2 expression. J. Immunol. 201, 3343–3351 (2018).

Article  CAS  PubMed  Google Scholar 

Ramon, S., Gao, F., Serhan, C. N. & Phipps, R. P. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J. Immunol. 189, 1036–1042 (2012).